The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma

Table 10

The effect of different bortezomib doses on bone marrow cell apoptosis, viability, and necrosis (average values).

Genotypes	Bortezomib/DMSO
	Control 0.1% DMSO (0 nM)	value	1 nM	value	2 nM	value	4 nM	value	8 nM	value	12 nM	value
Apoptotic cells (%)
Mean	5.45	—	15.44	—	17.49	—	25.55	—	37.52	—	47.68	—
NOD2/CARD15 wild type	5.10	0.30	15.51	0.92	17.29	0.66	26.18	0.37	39.64	0.018	49.48	0.03
NOD2/CARD15 mutated	6.96		15.10		18.34		22.78		28.28		39.86
PSMA6 CC	5.46	0.97	14.79	0.49	17.65	0.76	24.66	0.30	35.58	0.07	47.15	0.61
PSMA6 CG+GG	5.41		17.39		17.0		28.19		43.33		49.25
CC+wild type	5.19	0.55	14.46	0.78	17.52	0.84	25.09	0.81	37.07	0.34	48.86	0.45
CG+GG+mutated	6.75		12.97		18.25		23.75		30.77		43.97
Necrotic cells (%)
Mean	2.43	—	4.35	—	6.65	—	11.69	—	12.84	—	14.93	—
NOD2/CARD15 wild type	2.60	0.47	4.38	0.87	6.61	0.91	12.09	0.36	13.15	0.52	15.37	0.31
NOD2/CARD15 mutated	1.68		4.21		6.78		9.97		11.43		13.02
PSMA6 CC	2.38	0.85	4.64	0.23	6.66	0.97	11.27	0.42	12.76	0.91	14.99	0.90
PSMA6 CG+GG	2.58		3.48		6.61		12.94		13.04		14.75
CC+wild type	2.58	0.93	4.63	0.56	6.67	0.88	11.92	0.66	13.09	0.85	15.46	0.71
CG+GG+mutated	2.42		3.63		7.05		13.37		12.30		14.22
Viable cells (%)
Mean	89.17	—	79.58	—	76.08	—	66.18	—	59.71	—	53.32	—
NOD2/CARD15 wild type	89.56	0.42	78.91	0.40	76.16	0.91	65.62	0.49	58.60	0.14	52.83	0.42
NOD2/CARD15 mutated	87.49		82.47		75.69		68.60		64.51		55.43
PSMA6 CC	90.06	0.12	80.65	0.26	75.39	0.48	66.88	0.47	60.69	0.28	53.93	0.40
PSMA6 CG+GG	86.48		76.35		78.13		64.07		56.76		51.47
CC+wild type	90.40	0.29	79.99	0.95	75.34	0.95	66.37	0.95	59.71	0.73	53.05	0.61
CG+GG+mutated	86.85		79.61		75.74		66.80		61.67		50.45